Pee Safe Secures $3 Million In Series B Funding The fund raised will be utilized to expand the retail presence in India, expand overseas with an omnichannel approach and allocate additional resources to marketing and awareness initiatives

By Teena Jose

Opinions expressed by Entrepreneur contributors are their own.

You're reading Entrepreneur India, an international franchise of Entrepreneur Media.

Pee Safe

Pee Safe, a hygiene and wellness brand owned by Redcliffe Hygiene Private Limited, has partially closed their Series B round. The company has received $3 million out of their total round size of $6 million. The funding was led by Natco Pharma Limited, a leading pharmaceutical company, and Rainmatter Health, supported by Nithin Kamath and Nikhil Kamath, founders of Zerodha. Alkemi Growth Capital, an existing investor, also participated in the round.

According to the company, the newly acquired funds will be utilized to expand the retail presence in India, expand overseas with an omnichannel approach and allocate additional resources to marketing and awareness initiatives.

"We are thrilled to secure strategic funding from esteemed pharmaceutical and wellness players like Natco Pharma and Rainmatter. This funding will accelerate our expansion efforts and establish us as the leading brand in the rapidly growing intimate wellness sector, which boasts a remarkable CAGR of 16%. Over the past five years, Pee Safe has achieved a remarkable growth rate of 100% CAGR, surpassing market expectations," said Vikas Bagaria, the founder and CEO, Pee Safe.

Pee Safe was established with the primary goal of addressing a significant concern for women: the risk of Urinary Tract Infections resulting from unsanitary toilet seats and the lack of access to hygienic public restrooms.

The company also claimed that it has served over 6 million customers with over 7 lakh registered customers on their website, and impacted the lives of over 2 lakh menstruators from underprivileged backgrounds through awareness drives and donated over a million menstrual care products.

"The vast majority of Indian women don't have access to safe menstrual and personal hygiene products. This is due to a lack of awareness and access, which causes preventable health issues like urinary tract infections (UTI) among millions of Indian women. Making these products widely available is the need of the hour, and we are thrilled that Pee Safe is tackling these challenges. Helping Indians live healthier lives is a cause that we identify closely with at Rainmatter, and we are happy to be a part of this journey," said Dilip Kumar, Head of Investments, Rainmatter Health (backed by Zerodha).

Teena Jose

News Desk Reporter with Entrepreneur India

Teena is a post graduate in financial journalism. She has an avid interest in content creation, digital media and fashion.
Business News

JPMorgan Shuts Down Internal Message Board Comments After Employees React to Return-to-Office Mandate

Employees were given the option to leave comments about the RTO mandate with their first and last names on display — and they did not hold back.

Business Ideas

70 Small Business Ideas to Start in 2025

We put together a list of the best, most profitable small business ideas for entrepreneurs to pursue in 2025.

News and Trends

Recur Club Announces Credit Offerings for Startups Beyond Series A and SMEs

In FY 24–25, the platform also plans to deploy an additional INR 2000 crores through its Recur Swift program for startups.

News and Trends

NeoSapien Secures INR 80 Lakhs on Shark Tank India 4 for AI Wearable

Founded in 2024 by Dhananjay Yadav and Aryan Yadav, NeoSapien aims to integrate AI into daily life through its wearable technology

News and Trends

PAG Acquires Majority Stake in Pharma Packaging Player Pravesha Industries

This move underscores PAG's continued focus on India's burgeoning packaging industry, following its recent investment in Manjushree Technopack.

News and Trends

Quadria Capital Invests USD 100 Mn in Hyderabad-Based Aragen Life Sciences to Drive Global Expansion

This funding, which values Aragen at approximately USD 1.4 billion, involves a significant capital infusion along with a minor secondary sale by existing investors.